Monopar Therapeutics Is Trading Higher On Announcing Its uPA Radiotracer Along With Pet Imaging Can Detect Breast Cancer

Monopar Therapeutics Inc MNPR has announced the publication of a peer-reviewed study that demonstrated Monopar's Urokinase plasminogen activator (uPA) antibody fragment radiotracer could potentially identify breast cancers with uPA overexpression and monitor uPA activity during treatment using PET imaging.
uPA is an established biomarker in current breast cancer clinical practice guidelines, and its presence is used to select appropriate drug treatment.
Monopar has a panel of proprietary antibodies and antibody fragments to uPA and its receptor uPAR (such as MNPR-101).
The company's antibody fragment (ATN-291 F(ab')2) conjugated to a copper radiotracer enabled rapid PET visualization of tumors with uPA overexpression in a human breast cancer model in mice.
Price Action: MNPR shares are up 12.3% at $6.47 in market trading hours on the last check Tuesday.